Who is sponsoring NCT06085001?

NCT06085001 is sponsored by Croydon University Hospital.

What drugs are being tested in NCT06085001?

Interventions in NCT06085001: Lumella finger prick blood test.

What condition does NCT06085001 study?

NCT06085001 studies Preeclampsia, Pregnancy Related, Hypertension.

Is NCT06085001 still recruiting?

NCT06085001 is currently status unknown. Last updated 16 October 2023.

Last reviewed 2023-10-16 · How we verify

NCT06085001: Lumella

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Use of Lumella-glycosylated Fibronectin for Diagnosis of Preeclampsia

Status unknown Last updated 16 October 2023

What this trial tests

trial testing Lumella finger prick blood test in Preeclampsia in 50 participants. Status unknown.

Timeline

10 November 2023

Primary endpoint
30 May 2024

30 August 2024

Quick facts

Lead sponsor	Croydon University Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	50
Start date	10 November 2023
Primary completion	30 May 2024
Estimated completion	30 August 2024
Sites	1 location across United Kingdom

Drugs / interventions tested

Lumella finger prick blood test

Conditions studied

Preeclampsia — all drugs for Preeclampsia →
Pregnancy Related — all drugs for Pregnancy Related →
Hypertension — all drugs for Hypertension →

Sponsor

Croydon University Hospital

Who can join

Eligibility, female only, with Preeclampsia or Pregnancy Related. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

women with symptoms of preeclampsia from antenatal clinic or triage will be offered Lumella test along with traditional blood tests. If Lumella test is positive which will be compared with the traditional blood test results. Once 50 positive cases have been analysed the study results will be submitted to NICE.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Preeclampsia

Currently open trials in the same condition.

NCT06953115 — Vagal Stimulation Therapy and Preeclampsia · NA · recruiting
NCT06333652 — Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders · Phase 2 · recruiting
NCT07282171 — A Study to Investigate the Safety, Pharmacodynamic and Pharmacokinetic Characteristics of CBP-4888 in Hospitalized Parti · Phase 1 · recruiting
NCT07345845 — MR and Inflammation After Preeclampsia · EARLY_PHASE1 · active not recruiting
NCT07041281 — Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06085001 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Croydon University Hospital
Last refreshed: 16 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06085001.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing